JupiteX Get the app
Health & Medicine18 Nov 2026 · about 7 min

FDA flags potential VEGF-related safety concern in Summit rejection letter

The brief

The available excerpt says the FDA flagged a safety issue while reviewing ivonescimab, a cancer drug from Summit Therapeutics and Akeso that was rejected. But the text ends before it identifies the concern. It would be misleading to name a particular side effect or explain what the FDA found from this excerpt alone. That missing detail matters because VEGF-blocking drugs can have effects beyond tumors, and the precise safety issue would help readers understand the FDA’s concern. The excerpt supplies no event, patient group, trial result, or risk estimate. It also does not say whether the concern involved ivonescimab alone or the broader class of VEGF-targeting treatments. The only supported conclusion is that the FDA raised a safety issue in its review and that ivonescimab was rejected. The excerpt gives no additional explanation, response from either company, or next step. More of the rejection letter or article would be needed to answer what specific VEGF-related risk the FDA identified.

01

What potential VEGF-related safety concern did the FDA flag in its rejection letter for ivonescimab?

The available excerpt says the FDA flagged a safety issue while reviewing ivonescimab, a cancer drug from Summit Therapeutics and Akeso that was rejected. But the text ends before it identifies the concern. It would be misleading to name a particular side effect or explain what the FDA found from this excerpt alone.

That missing detail matters because VEGF-blocking drugs can have effects beyond tumors, and the precise safety issue would help readers understand the FDA’s concern. The excerpt supplies no event, patient group, trial result, or risk estimate. It also does not say whether the concern involved ivonescimab alone or the broader class of VEGF-targeting treatments.

The only supported conclusion is that the FDA raised a safety issue in its review and that ivonescimab was rejected. The excerpt gives no additional explanation, response from either company, or next step. More of the rejection letter or article would be needed to answer what specific VEGF-related risk the FDA identified.

02

What is VEGF, and what does it normally do in the body?

VEGF stands for vascular endothelial growth factor. It is a group of signaling proteins that help regulate blood vessel formation. The excerpt mentions a VEGF-related safety issue but does not explain the term, so this definition draws on established biological knowledge.

Normally, VEGF signals cells lining blood vessels to grow, divide, and form new vessels. The body uses this system during development and to help restore blood supply to tissues, including during wound healing. VEGF also helps maintain the function of blood vessels. Its activity is regulated; it is not simply a signal that should always be switched off or turned up.

This normal role helps explain why drugs that block VEGF can affect healthy tissues as well as tumors. Cancer treatments may interfere with the same signaling that supports blood vessels elsewhere in the body. The excerpt does not say which VEGF-related risk the FDA flagged for ivonescimab, so its specific concern cannot be inferred from the supplied text.

03

How many biological targets does ivonescimab act on, and what are they?

Ivonescimab is designed to engage two biological targets: PD-1 and VEGF. This answer uses established information about the drug, because the supplied excerpt names ivonescimab but does not state its targets. PD-1 is a protein involved in regulating immune responses; VEGF is a signal involved in blood vessel growth.

The drug is described in scientific sources as a bispecific antibody, meaning it is engineered to bind two different targets. The intended logic is to combine immune checkpoint activity directed at PD-1 with VEGF blockade. Those two actions address different processes relevant to cancer treatment: immune regulation and the formation of blood vessels that can support tumors.

The excerpt’s focus is narrower: it says the FDA flagged a safety issue in its review of the now-rejected drug. It gives no detail about the drug’s mechanism, trial results, or the particular risk. So while the two targets can be identified from established drug information, the excerpt alone cannot connect either target to the specific FDA concern.

04

Why can blocking VEGF cause safety problems for patients, not just affect tumors?

VEGF signaling is part of normal blood vessel growth and maintenance, not a process limited to cancer. That is why blocking VEGF can have effects beyond a tumor. The supplied excerpt says the FDA flagged a safety issue for ivonescimab, but it does not identify that issue; the biological explanation here is established background.

When a treatment inhibits VEGF, it can interfere with signals that help blood vessels form and function. In patients, medicines that block this pathway are associated with risks such as high blood pressure, bleeding, and impaired wound healing. Those are class-level examples, not findings that the excerpt attributes to ivonescimab or to the FDA’s rejection letter.

The balance between benefit and harm is important because the same pathway can support tumor blood vessels and normal tissues. Doctors and regulators consider the treatment’s risks alongside its potential benefits. The excerpt does not report a particular side effect, its frequency, or the evidence behind the FDA’s concern, so those details remain unknown here.

05

How does the FDA use safety evidence when deciding whether a cancer drug can be approved?

When reviewing a cancer drug, the FDA considers evidence about both benefits and harms. Safety evidence can include side effects seen in clinical studies, how serious they are, and whether the likely benefits justify the risks for the intended patients. This is general information about FDA drug review; the excerpt does not explain the agency’s specific reasoning for ivonescimab.

For ivonescimab, the only stated review detail is that the FDA flagged a safety issue. The excerpt does not describe the evidence, name a side effect, give a rate, or say how the safety concern compared with evidence of benefit. It also does not say whether other factors contributed to the rejection. No more specific conclusion can be drawn from the supplied text.

The safety concern is therefore relevant, but its weight in the decision is unclear from this excerpt. A complete account would need the FDA’s rejection letter or the full article. Without that information, it is not possible to explain what evidence regulators relied on, what they asked the companies to address, or whether the decision could change.

06

What other kinds of cancer treatments can target PD-1 or VEGF?

Cancer treatments can target PD-1 or VEGF through different medicines. The excerpt does not mention alternative drugs; these examples come from established knowledge of cancer treatment. PD-1 is targeted by immune checkpoint inhibitors, which are commonly monoclonal antibodies. VEGF signaling can be targeted by antibodies that bind VEGF or by medicines that block its receptors or related signaling.

For example, pembrolizumab and nivolumab are PD-1-blocking antibodies used in cancer care. Bevacizumab is an antibody that targets VEGF, while some small-molecule drugs inhibit VEGF receptors. These examples act on individual targets or pathways; they are not claims about what the FDA discussed in ivonescimab’s review.

Ivonescimab is designed to act on both PD-1 and VEGF, but the supplied excerpt gives no details of its mechanism or of other treatment options. It only reports that the FDA flagged a safety issue and that the drug was rejected. The examples help distinguish possible approaches, but they do not tell us what alternative the companies or FDA may consider.

07

How do tumors use new blood vessels to grow, and what is that process called?

Angiogenesis is the formation of new blood vessels from existing ones. Tumors can use this process to improve their access to oxygen and nutrients as they grow. The supplied excerpt mentions a VEGF-related safety issue but does not explain how tumors use blood vessels, so this account draws on established biological knowledge.

Tumor cells and nearby tissues can release signals, including VEGF, that encourage blood vessel cells to grow and form new branches. The resulting vessels can supply the tumor with blood. VEGF is one important signal in this process, but it is not the only factor involved in tumor growth or blood vessel formation.

This biology helps explain why cancer drugs may try to block VEGF signaling: limiting support from blood vessels may hinder a tumor. But VEGF also has normal functions in healthy tissues, which is one reason blocking it can raise safety questions. The excerpt does not state whether this mechanism was discussed in the FDA review or what specific safety concern led to ivonescimab’s rejection.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web